Official_Bellicum_Logo_RGB.jpg
Bellicum Pharmaceuticals Announces Closing of $25.0 Million Underwritten Offering
November 03, 2020 20:26 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the closing...
Official_Bellicum_Logo_RGB.jpg
Bellicum Announces $25.0 Million Underwritten Offering Priced At-The-Market
October 29, 2020 17:16 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the pricing...
Official_Bellicum_Logo_RGB.jpg
Bellicum Announces Interim BPX-601 Data and Corporate Restructuring
October 29, 2020 17:15 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced interim data...
Official_Bellicum_Logo_RGB.jpg
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 30, 2020 16:07 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
Official_Bellicum_Logo_RGB.jpg
Bellicum to Participate in Two Upcoming Virtual Conferences
September 28, 2020 07:30 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that...
Official_Bellicum_Logo_RGB.jpg
Bellicum to Participate in Two Upcoming Virtual Investor Conferences
September 02, 2020 07:30 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that...
Official_Bellicum_Logo_RGB.jpg
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 31, 2020 16:07 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
Official_Bellicum_Logo_RGB.jpg
Bellicum Reports Second Quarter 2020 Financial Results and Provides Operational Update
August 06, 2020 16:05 ET | Bellicum Pharmaceuticals, Inc.
Received FDA IND clearance to initiate Phase 1/2 clinical trial for BPX-603 for HER2+ solid tumors Initial data for BPX-601 cohort 5C to be presented at a medical meeting by the end of 2020 ...
Official_Bellicum_Logo_RGB.jpg
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 31, 2020 16:08 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, July 31, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
Official_Bellicum_Logo_RGB.jpg
Bellicum to Report Second Quarter 2020 Financial Results and Provide Corporate Update
July 30, 2020 16:05 ET | Bellicum Pharmaceuticals, Inc.
HOUSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it will...